Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01742793 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid)…(RID) | Phase 1 | terminated | Dec 5, 2012 | Yale University | The study was terminated due to withdrawal of institutional support, Phase II never began. | Other (stated, no rule matched) |
| NCT02784483 | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic… | Phase 1 | terminated | May 27, 2016 | Yale University | Based on FDA requirements | Other (stated, no rule matched) |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Oct 7, 2016 | Bayer | Due to the changes of standard of care and the slow recruitment of participants. | Enrollment / accrual |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory… | Phase 2 | terminated | Sep 21, 2011 | NYU Langone Health | PI left institution. | Investigator |
| NCT03328936 | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | Phase 2 | withdrawn | Nov 1, 2017 | Ohio State University Comprehensive Cancer Center | Sponsor decision | Sponsor / business decision |
| NCT03173430 | Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell… | Early Phase 1 | terminated | Jun 1, 2017 | Abramson Cancer Center at Penn Medicine | PI decided to close study due to slow accrual. | Enrollment / accrual |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Phase 1 | withdrawn | Aug 2, 2019 | Dana-Farber Cancer Institute | Business development reasons. | Sponsor / business decision |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple…(SMR-3184) | Phase 1 / Phase 2 | terminated | Jun 23, 2017 | Allarity Therapeutics | The study was terminated early due to sponsors decision | Other (stated, no rule matched) |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy,… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2018 | M.D. Anderson Cancer Center | Lack of Funding | Funding |
| NCT04243109 | Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients…(POCODEX) | Phase 2 | terminated | Jan 28, 2020 | Maimónides Biomedical Research Institute of Córdoba | Low recruitment rate. Lack of interest of the sponsor. | Enrollment / accrual |
| NCT01789723 | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's… | Phase 1 | withdrawn | Feb 12, 2013 | Acrotech Biopharma Inc. | not stated | Not stated |
| NCT02773550 | Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in…(Velcadito) | Phase 4 | terminated | May 16, 2016 | Basque Health Service | Low recruiment. | Other (stated, no rule matched) |
| NCT03269552 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia… | Phase 2 | terminated | Aug 31, 2017 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive…(IDEALL) | Phase 2 | withdrawn | Aug 1, 2018 | Takeda | Business decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT03670901 | A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With… | Phase 3 | terminated | Sep 14, 2018 | JHL Biotech, Inc. | The development was stopped due to company's strategy consideration | Sponsor / business decision |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | Phase 2 | terminated | Jun 8, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With… | N/A | terminated | May 22, 2014 | Masonic Cancer Center, University of Minnesota | Replaced by another study. | Other (stated, no rule matched) |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched… | Phase 1 | terminated | Sep 9, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01445340 | Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | Phase 1 | terminated | Oct 3, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 | terminated | Aug 20, 2001 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01571726 | Imaging Studies and the Development of Multiple Myeloma | Phase 2 | withdrawn | Apr 5, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01660997 | MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma | Phase 2 | withdrawn | Aug 9, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00582166 | Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance | Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | See 'Limitations and Caveats' section | Other (stated, no rule matched) |
| NCT01647165 | Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for… | Phase 2 | withdrawn | Jul 20, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02682953 | Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers | Phase 2 | withdrawn | Feb 17, 2016 | University of Maryland, Baltimore | subject recruitment not feasible due to standard care changes | Enrollment / accrual |
| NCT01239368 | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | Phase 1 / Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | Terminated due to insufficient accrual. | Enrollment / accrual |
| NCT01251913 | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration… | — | terminated | Dec 2, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02112045 | A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple… | Phase 2 | terminated | Apr 11, 2014 | Washington University School of Medicine | Terminated due to results of interim analysis | Efficacy / futility |
| NCT00655668 | A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory…(EXPECT) | Phase 2 | terminated | Apr 10, 2008 | Celgene | Decision not to pursue as single agent in the study population. | Other (stated, no rule matched) |
| NCT00765102 | Trial of Romidepsin and Bortezomib for Multiple Myeloma | Phase 2 | terminated | Oct 2, 2008 | Celgene | There was a change in the Sponsor's research strategy; safety concerns were not a factor. | Safety / toxicity |
| NCT02087878 | A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel…(HSTCL) | — | withdrawn | Mar 14, 2014 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 14, 2015 | Pharmacyclics LLC. | After completing Phase 1, the Sponsor elected not to move forward with Phase 2. | Other (stated, no rule matched) |
| NCT01021423 | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion…(RENEW) | Phase 3 | terminated | Nov 30, 2009 | Celgene | Terminated by sponsor due to new unpublished data that rendered the current design of the study no… | Safety / toxicity |
| NCT01248455 | A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma | Phase 2 | terminated | Nov 25, 2010 | National Cancer Institute (NCI) | Lack of patients meeting the defined primary obj. (50% decline in M-protein). | Other (stated, no rule matched) |
| NCT01772719 | Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and… | N/A | terminated | Jan 21, 2013 | University of Louisville | Principal Investigator left institution-study not continued | Investigator |
| NCT01754870 | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by… | Phase 2 | withdrawn | Dec 21, 2012 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT02579824 | Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in… | Phase 1 | terminated | Oct 20, 2015 | M.D. Anderson Cancer Center | stopped prematurely | Other (stated, no rule matched) |
| NCT00109109 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced… | Phase 1 | terminated | Apr 25, 2005 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT03952832 | Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma | Phase 2 | withdrawn | May 16, 2019 | City of Hope Medical Center | Budget issues | Funding |
| NCT02289222 | 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in… | Phase 1 / Phase 2 | terminated | Nov 13, 2014 | Ashraf Badros | Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the… | Other (stated, no rule matched) |
| NCT01783522 | Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving… | Phase 2 | terminated | Feb 5, 2013 | Beth Faiman | Research Cancelled | Other (stated, no rule matched) |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT02043860 | Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for…(BMT-02) | Phase 1 | terminated | Jan 23, 2014 | University of Illinois at Chicago | low accrual | Enrollment / accrual |
| NCT02729961 | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic… | Phase 1 / Phase 2 | withdrawn | Apr 6, 2016 | University of Washington | Administrative closure | Other (stated, no rule matched) |
| NCT02776891 | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH… | Phase 2 | withdrawn | May 18, 2016 | University of California, San Francisco | Unexpected dose production issues prevented study start up | Other (stated, no rule matched) |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis | Phase 1 | terminated | Nov 11, 2015 | GlaxoSmithKline | A new study will be initiated in order to specifically investigate cardiac safety | Safety / toxicity |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | Phase 1 | terminated | May 27, 2016 | Michael Choi | lack of funding | Funding |
| NCT03379584 | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma | Phase 1 | terminated | Dec 20, 2017 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 4, 2020source: clinicaltrials